MA45455A - Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées - Google Patents
Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associéesInfo
- Publication number
- MA45455A MA45455A MA045455A MA45455A MA45455A MA 45455 A MA45455 A MA 45455A MA 045455 A MA045455 A MA 045455A MA 45455 A MA45455 A MA 45455A MA 45455 A MA45455 A MA 45455A
- Authority
- MA
- Morocco
- Prior art keywords
- epitopes
- bind
- molecules
- identifying
- peptidic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662355211P | 2016-06-27 | 2016-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45455A true MA45455A (fr) | 2019-05-01 |
Family
ID=59363220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045455A MA45455A (fr) | 2016-06-27 | 2017-06-27 | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200182884A1 (fr) |
EP (1) | EP3475446A1 (fr) |
JP (1) | JP6987134B2 (fr) |
CN (1) | CN110291402B (fr) |
CA (1) | CA3028002A1 (fr) |
MA (1) | MA45455A (fr) |
WO (1) | WO2018005559A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2569436T (lt) | 2010-05-14 | 2018-03-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
CA2904001C (fr) * | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Vecteurs cytomegalovirus permettant la commande du ciblage de lymphocyte t |
KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
WO2016011293A1 (fr) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Cytomégalovirus humain comprenant des antigènes exogènes |
CN108064304A (zh) | 2015-02-10 | 2018-05-22 | 俄勒冈健康与科学大学 | 可用于产生非典型cd8+ t细胞应答的方法和组合物 |
EP3377636A4 (fr) | 2015-11-20 | 2019-11-06 | Oregon Health & Science University | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
KR102565256B1 (ko) | 2017-02-12 | 2023-08-08 | 바이오엔테크 유에스 인크. | Hla 기반 방법 및 조성물, 및 이들의 용도 |
EP3568469A4 (fr) * | 2017-02-21 | 2020-11-11 | Eutilex Co., Ltd. | Compositions de cellules car-t dirigées contre hla-dr et leurs procédés de fabrication et d'utilisation |
CA3080546A1 (fr) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | Molecules de liaison specifique a l'hpv |
CN111712254A (zh) | 2017-12-23 | 2020-09-25 | 鲁比厄斯治疗法股份有限公司 | 人工抗原呈递细胞和使用方法 |
EP3755371A4 (fr) * | 2018-02-23 | 2021-11-24 | Abexxa Biologics, Inc. | Traitement anticancéreux combiné avec des agents anticancéreux et des anticorps ciblant un complexe comprenant un hla-i non classique et un néo-antigène |
BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
EP3539552A1 (fr) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation et expansion de cellules nk nkg2c+ |
TWI840351B (zh) | 2018-04-05 | 2024-05-01 | 美商奇諾治療有限公司 | T細胞受體及表現其之工程化細胞 |
US10557216B2 (en) * | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
CA3100775A1 (fr) * | 2018-05-18 | 2019-11-21 | Children's National Medical Center | Therapie ciblee amelioree par lymphocytes t |
KR20210043623A (ko) | 2018-08-10 | 2021-04-21 | 주식회사 유틸렉스 | Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포 |
CA3108716A1 (fr) * | 2018-08-14 | 2020-02-20 | Board Of Regents, The University Of Texas Systems | Peptides de sequencage a molecule unique lies au complexe majeur d'histocompatibilite |
AU2019394875A1 (en) | 2018-12-03 | 2021-06-17 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including HLA-E and HLA-G molecules and methods of use |
MX2021007556A (es) | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
EP3918063A4 (fr) * | 2019-01-31 | 2022-12-14 | NantBio, Inc. | Bibliothèque d'anticorps d'affichage d'arnm et procédés |
CA3130750A1 (fr) | 2019-02-20 | 2020-08-27 | Rubius Therapeutics, Inc. | Cellules erythroides modifiees comprenant des polypeptides de presentation d'antigene chargeables et procedes d'utilisation |
CN109913414A (zh) * | 2019-03-21 | 2019-06-21 | 吉林省银丰生物工程技术有限公司 | 肝癌afp特异性人工抗原递呈细胞诱导试剂盒 |
AU2020322221A1 (en) * | 2019-07-26 | 2022-03-24 | Janssen Biotech, Inc. | Anti-hK2 chimeric antigen receptor (CAR) |
WO2021087851A1 (fr) * | 2019-11-07 | 2021-05-14 | 苏州工业园区唯可达生物科技有限公司 | Vecteur viral recombinant, composition immunogène le contenant, et son utilisation |
JP2023513263A (ja) | 2020-02-10 | 2023-03-30 | ルビウス セラピューティクス, インコーポレイテッド | Hla-gポリペプチドを含む操作された赤血球系細胞およびその使用方法 |
CN111116716B (zh) * | 2020-03-03 | 2022-03-01 | 中国医科大学 | 一种与骨髓瘤细胞高表达抗原hla-e特异性结合的多肽及其用途 |
CN111429965B (zh) * | 2020-03-19 | 2023-04-07 | 西安交通大学 | 一种基于多连体特征的t细胞受体对应表位预测方法 |
CN112285347B (zh) * | 2020-09-30 | 2023-12-22 | 西北农林科技大学 | 一种猪血清样中病原抗体elisa检测试剂盒 |
WO2024081807A2 (fr) * | 2022-10-12 | 2024-04-18 | Massachusetts Institute Of Technology | Méthodes d'échelle de bibliothèque pour analyse fonctionnelle de polypeptide |
Family Cites Families (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983001A (en) | 1972-05-10 | 1976-09-28 | Ceskoslovenska Akademie Ved | Isolation of biologically active compounds by affinity chromatography |
US4213860A (en) | 1976-06-30 | 1980-07-22 | Board of Regents, State of Florida for and on behalf of the University of Florida | Affinity chromatography and substrate useful therefor |
GB1602432A (en) | 1976-12-15 | 1981-11-11 | Atomic Energy Authority Uk | Affinity chromatography |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4175182A (en) | 1978-07-03 | 1979-11-20 | Research Corporation | Separation of high-activity heparin by affinity chromatography on supported protamine |
DE3271828D1 (en) | 1981-04-27 | 1986-07-31 | Health Lab Service Board | High pressure liquid affinity chromatography |
DE3275431D1 (en) | 1981-04-27 | 1987-03-19 | Health Lab Service Board | Affinity chromatography using metal ions |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5171534A (en) | 1984-01-16 | 1992-12-15 | California Institute Of Technology | Automated DNA sequencing technique |
US5821058A (en) | 1984-01-16 | 1998-10-13 | California Institute Of Technology | Automated DNA sequencing technique |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US4811218A (en) | 1986-06-02 | 1989-03-07 | Applied Biosystems, Inc. | Real time scanning electrophoresis apparatus for DNA sequencing |
IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0277773A1 (fr) | 1987-01-30 | 1988-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Cytomégalovirus hybride et vaccin |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
CA1340807C (fr) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Procede d'amplification d'une sequence d'acide nucleique |
JP2650159B2 (ja) | 1988-02-24 | 1997-09-03 | アクゾ・ノベル・エヌ・ベー | 核酸増幅方法 |
SE8801070D0 (sv) | 1988-03-23 | 1988-03-23 | Pharmacia Ab | Method for immobilizing a dna sequence on a solid support |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US4962020A (en) | 1988-07-12 | 1990-10-09 | President And Fellows Of Harvard College | DNA sequencing |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
EP0452342B1 (fr) | 1988-12-28 | 1994-11-30 | MILTENYI, Stefan | Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques |
US5043062A (en) | 1989-02-21 | 1991-08-27 | Eastman Kodak Company | High performance affinity chromatography column comprising non-porous, nondisperse polymeric packing material |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
KR0185192B1 (ko) | 1989-10-05 | 1999-04-01 | 제임스 더블유. 데이비 | 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
JP4251406B2 (ja) | 1990-04-05 | 2009-04-08 | クレア,ロベルト | ウォーク―スルー突然変異誘発 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
EP0575485A1 (fr) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Procede de developpement de mini-proteines de liaison |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
GB9208733D0 (en) | 1992-04-22 | 1992-06-10 | Medical Res Council | Dna sequencing method |
NZ255683A (en) | 1992-08-07 | 1996-08-27 | Cytel Corp | Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif |
JPH08509857A (ja) | 1993-01-07 | 1996-10-22 | シーケノム・インコーポレーテッド | マススペクトロメトリーによるdna配列決定法 |
US5374527A (en) | 1993-01-21 | 1994-12-20 | Applied Biosystems, Inc. | High resolution DNA sequencing method using low viscosity medium |
US5989565A (en) | 1993-01-29 | 1999-11-23 | University Of Pittsburgh | Elution and identification of T cell epitopes from viable cells |
AU673245B2 (en) | 1993-02-01 | 1996-10-31 | Seq, Ltd. | Methods and apparatus for DNA sequencing |
NZ263050A (en) | 1993-03-05 | 1997-11-24 | Cytel Corp | Compositions of immunogenic peptides with hla-a2.1 binding motifs |
EP0689610B1 (fr) | 1993-03-19 | 2002-07-03 | Sequenom, Inc. | Sequencage de l'adn au moyen de la spectrometrie de masse par degradation a l'exonuclease |
US5422252A (en) | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
US5654419A (en) | 1994-02-01 | 1997-08-05 | The Regents Of The University Of California | Fluorescent labels and their use in separations |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
WO1996013593A2 (fr) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Recepteurs de lymphocites t monocatenaires solubles |
WO1996018105A1 (fr) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Recepteur de lymphocyte t monocatenaire |
US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US5721354A (en) | 1995-03-31 | 1998-02-24 | Aviron | Human cytomegalovirus DNA sequences |
US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
AU714486B2 (en) | 1995-11-21 | 2000-01-06 | Yale University | Unimolecular segment amplification and detection |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (fr) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple |
US5846727A (en) | 1996-06-06 | 1998-12-08 | Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College | Microsystem for rapid DNA sequencing |
GB9618050D0 (en) | 1996-08-29 | 1996-10-09 | Cancer Res Campaign Tech | Global amplification of nucleic acids |
DE69739163D1 (de) | 1996-10-17 | 2009-01-22 | Mitsubishi Chem Corp | Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen |
US5858671A (en) | 1996-11-01 | 1999-01-12 | The University Of Iowa Research Foundation | Iterative and regenerative DNA sequencing method |
US6258533B1 (en) | 1996-11-01 | 2001-07-10 | The University Of Iowa Research Foundation | Iterative and regenerative DNA sequencing method |
US5876934A (en) | 1996-12-18 | 1999-03-02 | Pharmacia Biotech Inc. | DNA sequencing method |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
CN1238366C (zh) | 1997-01-21 | 2006-01-25 | 综合医院公司 | 利用rna-蛋白融合体筛选蛋白 |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖t細胞レセプタータンパク質 |
SK17332000A3 (sk) | 1998-05-19 | 2001-06-11 | Avidex Limited | Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby |
JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
EP1117791A2 (fr) * | 1998-10-05 | 2001-07-25 | Ludwig Institute For Cancer Research | Antigenes associes au cancer et leurs utilisations |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
WO2000023573A2 (fr) | 1998-10-20 | 2000-04-27 | City Of Hope | Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿ |
AU775997B2 (en) | 1998-12-02 | 2004-08-19 | Bristol-Myers Squibb Company | DNA-protein fusions and uses thereof |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
DE19910044A1 (de) | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
US6385581B1 (en) | 1999-05-05 | 2002-05-07 | Stanley W. Stephenson | System and method of providing emotive background sound to text |
BR0010322A (pt) * | 1999-05-06 | 2002-04-09 | Univ Wake Forest | Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero |
DK2067788T3 (da) | 1999-05-18 | 2015-10-19 | Dyax Corp | Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
US6132997A (en) | 1999-05-28 | 2000-10-17 | Agilent Technologies | Method for linear mRNA amplification |
CA2377468C (fr) | 1999-07-27 | 2010-04-20 | Phylos, Inc. | Methodes de ligature d'un accepteur de peptide |
US6908612B2 (en) * | 1999-10-08 | 2005-06-21 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
ATE474931T1 (de) * | 2000-04-28 | 2010-08-15 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
AU2001265346A1 (en) | 2000-06-02 | 2001-12-17 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US6692954B1 (en) | 2000-11-03 | 2004-02-17 | The Scripps Research Institute | Generation of human cytomegalovirus yeast artificial chromosome recombinants |
JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Cd19特異的再指向免疫細胞 |
US20040087001A1 (en) | 2001-02-21 | 2004-05-06 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
NZ531208A (en) | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
WO2003070752A2 (fr) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Ligands de liaison au complexe mhc-peptide |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
WO2004015395A2 (fr) * | 2002-08-13 | 2004-02-19 | National Jewish Medical And Research Center | Methode d'identification d'epitopes de peptides presentes par cmh pour lymphocytes t |
WO2004033685A1 (fr) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Recepteurs de lymphocytes t de recombinaison a chaine unique |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US7754482B2 (en) | 2004-05-27 | 2010-07-13 | The Trustees Of The University Of Pennsylvania | Artificial antigen presenting cells and uses therefor |
US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
JP2008514685A (ja) | 2004-10-01 | 2008-05-08 | メディジーン リミテッド | 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するt細胞レセプター |
US8668564B2 (en) | 2005-01-24 | 2014-03-11 | Solution Champion Limited | Jackpot method and system |
WO2008120203A2 (fr) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Procédés de diagnostic et de traitement de maladies provoquées par le cytomégalovirus |
EP2856876B1 (fr) | 2007-03-30 | 2018-01-31 | Memorial Sloan-Kettering Cancer Center | Expression constitutive de ligands costimulants sur des lymphocytes T transférés de manière adoptive |
JP5456689B2 (ja) | 2007-12-07 | 2014-04-02 | ミルテンイ バイオテック ゲーエムベーハー | 試料を少なくとも2つの成分に分離する遠心分離機 |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
EP2316030B1 (fr) | 2008-07-25 | 2019-08-21 | Wagner, Richard W. | Procédés de criblage de protéines |
WO2010025177A1 (fr) | 2008-08-26 | 2010-03-04 | City Of Hope | Procédé et compositions pour fonctionnement amélioré d’effecteur antitumoral de lymphocytes t |
US9403904B2 (en) | 2008-11-07 | 2016-08-02 | Fabrus, Inc. | Anti-DLL4 antibodies and uses thereof |
US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
WO2011044186A1 (fr) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Récepteurs de lymphocytes t à chaîne unique humains |
SG177025A1 (en) | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
LT2569436T (lt) * | 2010-05-14 | 2018-03-12 | Oregon Health & Science University | Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas |
JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス, インコーポレイテッド | 新規のdna結合タンパク質及びその使用 |
SG190997A1 (en) | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
EP3798236B1 (fr) | 2011-03-15 | 2022-08-10 | X-Body, Inc. | Procédés de criblage d'anticorps |
US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
EP2694553B1 (fr) | 2011-04-01 | 2017-10-11 | Memorial Sloan-Kettering Cancer Center | Anticorps analogue au récepteur de cellule t spécifique pour un peptide wt1 présenté par hla-a2 |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
SG11201407175RA (en) | 2012-05-03 | 2014-12-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
KR102250696B1 (ko) | 2012-07-27 | 2021-05-12 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | T 세포 수용체 조작 |
SG11201501259QA (en) | 2012-08-20 | 2015-03-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
RU2020124583A (ru) | 2012-10-02 | 2020-08-03 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
DE112012007250T5 (de) | 2012-12-20 | 2015-10-08 | Mitsubishi Electric Corp. | Fahrzeuginterne Vorrichtung und Programm |
CA2904001C (fr) * | 2013-03-05 | 2021-07-13 | Oregon Health & Science University | Vecteurs cytomegalovirus permettant la commande du ciblage de lymphocyte t |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
US10627411B2 (en) * | 2014-03-27 | 2020-04-21 | British Columbia Cancer Agency Branch | T-cell epitope identification |
KR20170032406A (ko) * | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
WO2016011293A1 (fr) * | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Cytomégalovirus humain comprenant des antigènes exogènes |
CN104404040A (zh) * | 2014-12-11 | 2015-03-11 | 浙江大学 | 抗HCMV UL128基因82-102位点的siRNA序列及应用 |
CN108064304A (zh) | 2015-02-10 | 2018-05-22 | 俄勒冈健康与科学大学 | 可用于产生非典型cd8+ t细胞应答的方法和组合物 |
-
2017
- 2017-06-27 US US16/312,959 patent/US20200182884A1/en not_active Abandoned
- 2017-06-27 CN CN201780051883.0A patent/CN110291402B/zh active Active
- 2017-06-27 CA CA3028002A patent/CA3028002A1/fr active Pending
- 2017-06-27 MA MA045455A patent/MA45455A/fr unknown
- 2017-06-27 JP JP2019519629A patent/JP6987134B2/ja active Active
- 2017-06-27 EP EP17740520.6A patent/EP3475446A1/fr not_active Withdrawn
- 2017-06-27 WO PCT/US2017/039596 patent/WO2018005559A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CN110291402A (zh) | 2019-09-27 |
WO2018005559A1 (fr) | 2018-01-04 |
JP2019520089A (ja) | 2019-07-18 |
JP6987134B2 (ja) | 2021-12-22 |
US20200182884A1 (en) | 2020-06-11 |
EP3475446A1 (fr) | 2019-05-01 |
CN110291402B (zh) | 2023-09-01 |
CA3028002A1 (fr) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45455A (fr) | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées | |
FR23C1012I1 (fr) | Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations | |
MA43164A (fr) | Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations | |
MA42808A (fr) | Anticorps de liaison à l'il-8 et leurs utilisations | |
MA43308A (fr) | Molécules d'anticorps se liant à april et leurs utilisations | |
MA45712A (fr) | Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations | |
MA42059A (fr) | Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci | |
CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
MA46917A (fr) | Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation | |
IL267424A (en) | Methods and systems for analyzing nucleic acid molecules | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
ECSP17081420A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
MA44060A (fr) | Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations | |
MA47612A (fr) | Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
MA43874A (fr) | Constructions de liaison à l'antigène immunomodulateur multispécifique | |
ECSP17040521A (es) | Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales | |
BR112017011326A2 (pt) | anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune | |
MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
SG10202011027QA (en) | Dna monoclonal antibodies targeting checkpoint molecules | |
MA45491A (fr) | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés | |
MA45214A (fr) | Système de libération d'acariens utiles et utilisations associées | |
FR3036959B1 (fr) | Composition comprenant un polymere associatif anionique, un polymere fixant et un polymere anionique particuliers |